Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
3.465
-0.035 (-1.00%)
Dec 3, 2024, 12:04 PM EST - Market open
Atea Pharmaceuticals Employees
Atea Pharmaceuticals had 75 employees as of December 31, 2023. The number of employees increased by 5 or 7.14% compared to the previous year.
Employees
75
Change (1Y)
5
Growth (1Y)
7.14%
Revenue / Employee
n/a
Profits / Employee
-$2,320,080
Market Cap
292.66M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 75 | 5 | 7.14% |
Dec 31, 2022 | 70 | 11 | 18.64% |
Dec 31, 2021 | 59 | 20 | 51.28% |
Dec 31, 2020 | 39 | - | - |
Related Stocks
Company Name | Employees |
---|---|
OraSure Technologies | 638 |
uniQure | 480 |
Lexicon Pharmaceuticals | 285 |
LifeMD | 211 |
Tenaya Therapeutics | 140 |
Mersana Therapeutics | 123 |
Aclaris Therapeutics | 91 |
Ocugen | 65 |
AVIR News
- 7 days ago - Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference - GlobeNewsWire
- 18 days ago - Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 - GlobeNewsWire
- 23 days ago - Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway - GlobeNewsWire
- 4 months ago - Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript - Seeking Alpha